4SC AG (Frankfurt, Prime Standard: VSC), a discovery and development company of targeted small molecule drugs for autoimmune diseases and cancer, today announced topline results from its randomised, double-blind, placebo-controlled Phase IIb clinical trial COMPONENT in RA. The trial compared vidofludimus, an oral inhibitor of DHODH and pro-inflammatory cytokines (including IL-17A and IL-17F as well as INF-gamma), in rheumatoid arthritis patients on methotrexate background therapy versus methotrexate monotherapy over a treatment period of 13 weeks.

ACR20 response improvement of the 35 mg vidofludimus group compared to placebo was statistically significant (p

4 SC (TG:VSC)
Historical Stock Chart
From Dec 2024 to Jan 2025 Click Here for more 4 SC Charts.
4 SC (TG:VSC)
Historical Stock Chart
From Jan 2024 to Jan 2025 Click Here for more 4 SC Charts.